Denyes Nancy's Form 4 filing
aTYR PHARMA INCATYR · filed Jun 6, 2024
- Accession no.
- 0000950170-24-069680
- Filed
- Jun 6, 2024
- Trade date
- Jun 5, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $9.30K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Denyes NancyCIK 0001640869 | Officer (General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 5, 2024 | Common Stock | PPurchaseAcquired | +5,000 | $1.86F1 | +$9,300 | 22,267 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.835 to $1.87 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.